Immune-Related Long Non-coding RNA Constructs a Prognostic Signature of Ovarian Cancer

Area of Science:

• Oncology
• Genomics
• Immunology

Background:

• Ovarian cancer presents a significant global health challenge with poor patient prognosis.
• Identifying novel biomarkers is crucial for improving treatment outcomes and patient survival.

Purpose of the Study:

• To construct and validate an immune-related long non-coding RNA (lncRNA) signature for predicting ovarian cancer patient survival.
• To evaluate the signature's utility in assessing chemotherapy sensitivity and immune status.

Main Methods:

• Utilized normal and ovarian cancer patient data from GTEx and TCGA databases.
• Employed the least absolute shrinkage and selection operator (LASSO) Cox regression model to build the predictive signature.
• Determined risk groups using time-dependent Receiver Operating Characteristic (ROC) curve analysis.
• Validated the signature against clinical factors, chemo-sensitivity, and immune profiles.

Main Results:

• A signature comprising 145 differentially expressed immune-related lncRNAs (DEirlncRNAs) was established.
• The signature independently predicted overall survival in ovarian cancer patients.
• Low-risk patients demonstrated enhanced chemotherapy sensitivity and higher immunogenicity.

Conclusions:

• An effective DEirlncRNA-based signature was developed and validated.
• This signature accurately predicts prognosis, drug sensitivity, and immune status in ovarian cancer.
• The findings support improved prognostic estimation and personalized treatment approaches for ovarian cancer.